RE-021, sparsentan
RTRX-RE021-102 (QSC200850)
Phase 1 small_molecule completed
Quick answer
RE-021, sparsentan for Healthy Subjects is a Phase 1 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Travere Therapeutics
- Indication
- Healthy Subjects
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed